Clinical Trial

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Study acronym: PaTK02
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being treated with neoadjuvant chemoradiation (CR) or stereotactic body radiation therapy (SBRT). The Standard of Care (SOC) Control arm will be used as a benchmark for informal comparisons of efficacy, safety, and biomarkers.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT02446093
Lead Sponsor Candel Therapeutics, Inc.
Collaborators: Mayo Clinic
Conditions Borderline Resectable Pancreatic Adenocarcinoma
Enrollment 54 participants
Start Date 2015-10
Primary Completion 2025-12 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2024-01-08